Q-omics provides the consensus-scored RHO profile across patient tissues and cancer cell-line models. RHO expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RHO is differentially expressed in 8, with the highest sampling consensus in KICH. Additionally, RHO RNA expression shows 10,681 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KICH, and TGCT as cancer lineages where RHO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RHO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RHO survival associations across molecular data types. RHO RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RHO RNA expression–survival associations across cancer types. High RHO expression shows unfavorable associations in KIRP, KIRC, UVM, BLCA and LUSC, but favorable associations in SKCM. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for RHO RNA expression.
This table summarizes RHO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for RHO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RHO shows lower tumor expression in KICH and UCEC and higher tumor expression in LIHC, KIRC, HNSC and LUAD. The KICH box plot shows higher RHO RNA expression in normal versus tumor tissue (log2 FC = −0.071, t-test p < 0.001).
This table shows molecular features associated with RHO in patient tissues and cancer cell lines. In patient samples, RHO shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RHO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and STOMACH.
